- Another cautious session for risk assets yesterday with Europe, the UK and US markets relatively flat while the NASDAQ lagged behind with a decline.
- Novartis has issued a strong set of Q123 numbers and upgraded full year guidance. Previous guidance of Group and Innovative Medicines (IM) revenue growth was in the low-to-mid single digit range. This has been tightened to mid-single digit range. (Comment attached)
- A mixed session for core bond yields yesterday.
Overview
Committed to you, your financial future, and your journey there
Overview
Investment Solutions
Pension Solutions
SDIO
Application Forms – Intermediaries
Creating impact for your clients, their financial goals, and their future
Overview
Focused on your organisation, funding its growth, and unlocking its full potential
Debt Capital Markets
Probate Services
Dedicated to institutional wealth, stakeholder value, and a sustainable future
Overview
Investment Services
Stewardship
Supportive of you, your custodial vision, and your philanthropic goals
X